PATENT
Attorney Docket No. UCSD-04742

## AMENDMENTS TO THE CLAIMS

RECEIVED CENTRAL FAX CENTER

JAN 1-1 2007

1-87. (canceled)

88. (currently amended) A method for screening for modulators of <u>Thermomyces</u> <u>lanuginosus-y (TL-y)TL-y</u> comprising in operable order, the steps of:

- (a) providing:
  - (i) biologically active TL-γ, wherein the biological activity of said TL-γ comprises plus end-directed microtubule motor activity, and wherein said biologically active TL-γ comprises a motor domain sequence, wherein said motor domain sequence shares at least sixty percent sequence identity with the sequence comprising amino acids 1 through 357 of SEQ ID NO:1,
  - (ii) a candidate agent, wherein said candidate agent is provided in a test concentration and a control concentration, and
  - (iii) a testing assay;
- (b) contacting said biologically active TL-γ with said test concentration of said candidate agent in said testing assay to produce a test mixture;
- (c) contacting said biologically active TL-γ with said control concentration of said candidate agent in said testing assay to produce a control mixture;
- (d) assaying the level of TL-γ activity in said test mixture;
- (e) assaying the level of TL-γ activity in said control mixture;
- (f) comparing the TL-γ activity of said test mixture and said control mixture, wherein the TL-γ activity comprises one or more of microtubule gliding, microtubule binding, microtubule depolymerization and ATPase activity, and wherein differences in the TL-γ activity in said test mixture and said control mixture indicate that said candidate agent is a modulator of TL-γ.

PATENT
Attorney Docket No. UCSD-04742

- 89. (previously presented) The method of Claim 88, wherein said testing assay is selected from the group consisting of plus-end directed microtubule motor activity assays, binding activity assays, and ATPase activity assays.
- 90. (previously presented) The method of Claim 88, wherein said biologically active TL-γ specifically binds to polyclonal antibodies directed against TL-γ.
- 91. (previously presented) The method of Claim 88, wherein said biologically active TL- $\gamma$  is isolated from a cell sample.
- 92. (previously presented) The method of Claim 88, wherein said biologically active TLγ is recombinant.
  - 93. (canceled)
- 94. (previously presented) The method of Claim 88, wherein said candidate agent is selected from the group consisting of antibodies, proteins, oligonucleotides, peptides, saccharides, fatty acids, steroids, purines, and pyrimidines.
- 95. (previously presented) The method of Claim 88, wherein said testing assay is conducted in a high-throughput screen.

96-101. (canceled)

- 102. (new) The method of Claim 88, wherein said biologically active TL-γ further comprises amino acids 357 to 442 of SEQ ID NO:1.
- 103. (new) The method of Claim 102, wherein said biologically active TL-γ further comprises amino acids 443 to 601 of SEQ ID NO:1.

PATENT Attorney Docket No. UCSD-04742

104. (new) The method of Claim 103, wherein said biologically active TL- $\gamma$  further comprises amino acids 602 to 784 of SEQ ID NO:1.